Design and methods: Genomic DNA from patients and their unaffected relatives was extracted from peripheral blood leucocytes and amplified by PCR, followed by automated sequencing. Functional analysis was carried out using Y6 cells expressing wild type and mutant MC2R.
INTRODUCTION
Adrenocorticotropin (ACTH) resistance syndromes include familial glucocorticoid deficiency (FGD) and triple A syndrome, also known as Allgrove syndrome (1). These syndromes are rare autosomal recessive disorders characterized by early onset of primary adrenocortical insufficiency (2) . FGD was first described in 1959 by Shepard and colleagues (3) in two sisters with Addison's disease without mineralocorticoid deficiency. Clinical onset is usually in the first year of life, but it may occur later, and is accompanied by failure to thrive, hypoglycemia, convulsions and skin pigmentation (2) .
FGD is a genetically heterogeneous disease. FGD type 1 (OMIM#202200) includes patients with mutation in the ACTH receptor gene (MC2R), which accounts for 25% of FGD patients (1) . The MC2R is a member of the melanocortin receptor family in class A of the seven transmembrane domain G protein coupled receptors (GPCR), and signals through the cAMP pathways by stimulating adenylyl cyclase activity. The MC2R maps to 18p11.2 and comprises two exons; exon 1 is untranslated, and exon 2 encodes the entire sequence for the MC2R protein (4) . Since the first report of MC2R mutation (5) , several other mutations in the coding region of this gene have been described in segregation with FGD (for review see 1).
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More recently, mutations in MRAP, a gene encoding a small singletransmembrane domain protein known as melanocortin 2 receptor accessory protein, have been described in a subset of patients with ACTH resistance syndrome, comprising FGD type 2 (OMIM#607398) (6, 7) . Human MRAP is located at 21q22.1 and codes for two MRAP isoforms, MRAP-and MRAP-, that differentially regulate function of MC2R (8) . MRAP mutations are present in 20% of patients with FGD (6) . In more than 50% of FGD patients there is no known molecular genetic defect. In three of these families linkage was shown to markers on chromosome 8q (OMIM%609197), confirming the genetic heterogeneity of the disease (9) . The disease linking to chromosome 8q was defined as FGD type 3.
Triple A syndrome (AAAS, Allgrove syndrome, OMIM#231550) is a genetic disorder characterized by a triad of adrenal insufficiency, achalasia and alacrima, first described in 1978 by Allgrove et al. (10) . Patients with Triple A syndrome usually present with hypoglycemia due to adrenal insufficiency in the first decade of life but it can become manifest as late as the third decade of life (11) . Some patients may have progressive and disabling neurological manifestations due to central, peripheral, or autonomic nervous system involvement (12, 13) , often associated with mild mental retardation (11) . Genetic linkage analysis revealed a locus on chromosome 12q13 as a critical region in segregation with triple A syndrome (14) . Subsequently, a novel gene (AAAS), encoding a protein of 547 amino acids named ALADIN (for alacrima/achalasia/adrenal insufficiency/neurologic disorder), was identified as a molecular basis of triple A syndrome (13, 15) . This protein belongs to the WD-repeat family of regulatory proteins, and is located in the nuclear pore complexes (16) . Though Page 4 of 31 the function of ALADIN is not yet known, it has been suggested that it could regulate nucleocytoplasmic transport in specific cell types and the development of specific tissues (17). Homozygous and compound heterozygous mutations in the AAAS gene have been identified in several patients with triple A syndrome from different ethnic background (18, 19) .
In this study we aimed to describe the clinical findings and molecular analysis of MC2R, MRAP and AAAS of five Brazilian patients with ACTH resistance syndrome.
SUBJECTS AND METHODS
Blood samples were obtained from five patients with ACTH resistance syndrome and their relatives and also from 50 control individuals. This study was performed with informed consent and the approval of the University Hospital Ethics Committee.
DNA extraction, PCR and Sequencing
Genomic DNA was extracted from peripheral blood leucocytes collected from affected patients and unaffected relatives using QIAamp Blood Kit (QIAGEN, CA, USA), according to the manufacturer's protocol. PCR conditions and respective primers were based on previous reports for MC2R (20) and MRAP (6) . Amplification of AAAS was performed using specific primers as reported by Katsumata et al. (21) . Eight pairs of primers were used to amplify 16 exons of AAAS by PCR with the following annealing temperature: exons 1 and 2, 55°C; exons 3 and 4, 57°C; exons 5 and 6, 57°C; exon 7, 57°C; exon 8, 57°C; exons 9 and 10, 55°C; exons 11 to 14, 65°C, and exons 15 and 16, for 60 min. After incubation, cells and medium were harvested and cAMP was determined using cAMP Biotrak Enzymeimmunoassay System (Amersham Biosciences).
RESULTS

Clinical and Molecular findings
Patient 1
The female patient from consanguineous parents was born at term, with a birth weight of 3600g and length of 50 cm. In the neonatal period, she had seizures associated with hypoglycemia and at one year of age she had respiratory distress and seizures. At the age of four years she was admitted with fever, pneumonia, vomiting, seizures, hypoglycemia (blood glucose: 25 mg/dl) and hypothermia (35. which is located at the third transmembrane domain. Her parents and her young healthy brother were heterozygous for p.Gly116Val mutation.
Y6 cells expressing wild type MC2R showed a dose-response pattern of cAMP generation when stimulated with different doses of ACTH, however, p.Gly116Val MC2R failed to generate cAMP ( Figure 2 ).
Patient 2
The female patient from non-consanguineous parents was born at term with a birth weight of 4500g and length of 55 cm. She showed neonatal jaundice and at 11 months old she had convulsions with hypoglycemia and history of recurrent infections.
On examination, at one year and 10 months, she had height above the 97 th percentile, The female patient was born from consanguineous parents, and at age sixteen, she showed body weight loss, nausea, vomiting, hyporexia, excessive pigmentation of the The female patient from consanguineous parents was born at term with a birth weight of 3000g. At two years of age she had pneumonia and convulsions, which were followed by recurrent infections. At the age of six years she was diagnosed as having rheumatic fever. No clinical evidence of deficient tear production or achalasia was noted.
She had four dead brothers (two died of pneumonia before two years old and two died of unknown causes) and five healthy siblings. At age of seven years, she was admitted with excessive skin pigmentation, dehydration and nausea. Laboratory analysis showed Computerized tomography showed adrenal atrophy with no other abnormality. She has been on glucocorticoid therapy since 7 years of age with improvement of the symptoms.
The molecular analysis of MC2R, MRAP and AAAS genes of this patient showed no alterations.
Patient 5
The female patient, born from non-consanguineous parents, showed seizures associated with hypoglycemia and jaundice, and skin pigmentation in the neonatal period.
On examination, at 10 months, her height was above the 97 th percentile and she had mild skin pigmentation. Biochemical analysis showed undetectable basal cortisol levels (0.1 µg/dl) with elevated plasma ACTH (2970 pg/ml). Plasma 17-hydroxyprogesterone, aldosterone, plasma renin activity, and sodium and potassium were 4ng/dl, 4.8ng/dl, 1.6ng/ml/h, 137 mEq/l and 5.3 mEq/l, respectively. Ultrasonography showed no urogenital morphological abnormality. Glucocorticoid treatment improved her symptoms.
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None of the mutations described in the present study was found in control individuals.
DISCUSSION
In the present study we report the clinical findings and molecular analysis of four patients with FGD and one patient with triple A syndrome. We found mutations in the MC2R, MRAP and AAAS genes in three patients and no molecular alterations in these genes in two patients. Glycine is a member of a group of small and weakly polar amino acids that are conserved among the class A GPCR family, other members being alanine, serine, cysteine and threonine (28) . In the case of MC2R there is an interspecies conservation of glycine 116, as shown in Figure 6 . Moreover, in the melanocortin receptor family at the equivalent position to glycine 116 there is a serine residue in human MC1R and an alanine residue in human MC3R, MC4R and MC5R (29) . In addition, more than 80% of group-conservation of these small and weakly polar amino acids among other class A GPCR members has been described (28) . These amino acids play an important role in mediating helix-helix contact in the GPCRs, which is essential for receptor stabilization in an inactive conformation in the absence of ligand (30) . It is interesting to note that changing of serine 120, also a weakly polar amino acid located at the third transmembrane domain of MC2R, to a positively charged arginine (p.Ser120Arg) was
shown to be associated with FGD (31) . Functional study of p.Ser120Arg mutated MC2R demonstrated loss of function of the receptor, with no cAMP production after ACTH stimulation (32) . Therefore, the substitution of glycine at codon 116 by valine, a hydrophobic amino acid, in the ACTH receptor, as found in patient 1, is likely to impair its function, leading to ACTH resistance.
To investigate the functional effect of p.Gly116Val mutation, we carried out in vitro ACTH stimulation using Y6 cells transfected with wild type and mutant receptors.
Wild type MC2R showed cAMP generation in a dose response pattern, though a decrease of cAMP generation was observed at the highest dose of ACTH. This pattern of response has been described for other GPCRs (33, 34) , indicating loss or decrease of agonist efficacy in receptor activation. It is possible that desensitization of the MC2R may account for this, although it is notable that the wild type receptor does not show this response except possibly at high ACTH concentrations, and in mouse Y1 cells this receptor has been shown to desensitize relatively slowly in response to ACTH (35) .
Functional study of p.Gly116Val mutated MC2R showed a decreased cAMP generation when stimulated with ACTH. Therefore, this result confirms that the p.Gly116Val mutation affects signal transduction leading to ACTH resistance.
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The MC2R molecular analysis of patient 2 did not show alteration of this gene.
However, the molecular analysis of MRAP demonstrated a homozygous mutation with a substitution of guanine by adenine (g.727G>A) in the initiation codon (p.Met1Ile). This missense mutation was previously described by Metherell et al. (6) in nine patients from eight families. In their study, they showed that MRAP and MC2R interact and are colocalized in the endoplasmic reticulum and plasma membrane.
Though not frequent, mutations in the initiation codon have been reported as a cause of human diseases (36, 37, 38) . It has been demonstrated that initiation at non-AUG codons is inefficient in eukaryotic cells (39) . It has been shown in vitro that mutation at the initiation AUG prevent the RNA polymerase from recognizing the translation start codon (36) . interacts with Nup50, a nuclear pore complex protein (44) , suggesting that this interaction could be a novel mechanism of action of ACTH receptor (45) . The participation of changes in Nup50 function as a cause of ACTH resistance syndrome remains to be established.
In conclusion, we describe five patients with ACTH resistance syndrome with heterogeneous clinical findings, suggesting that excluding congenital adrenal hyperplasia, this rare syndrome should be investigated in infants and children with congenital adrenal insufficiency. Furthermore, besides genes already known to be involved in the FGD pathogenesis, other accessory proteins to ACTH receptor function may also underline the molecular basis of this disease. 
